Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444020 | 1.00 | OPRD1 (0.49) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL31258873 | 1.00 | OPRD1 (0.49) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL30034009 | 0.97 | OPRD1 (0.47) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL28665306 | 0.97 | OPRD1 (0.48) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL30366864 | 0.97 | OPRD1 (0.48) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL29565875 | 0.90 | KMT2A (0.54) | OPRD1KMT2AF2ACEALDH1A1 | |
| SCHEMBL28559438 | 0.90 | F2 (0.46) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL29591617 | 0.88 | OPRD1 (0.44) | OPRD1PREPKMT2AF2ACE | |
| SCHEMBL24378516 | 0.87 | OPRD1 (0.48) | OPRD1PREPKMT2AF2EPHX2 | |
| SCHEMBL29731400 | 0.87 | OPRD1 (0.48) | OPRD1PREPKMT2AF2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-3774838-B1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2022-08-10 | — | — | EP | disclosed |
| EP-3908323-A2 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11028123-B2 | Capping of unprotected amino groups during peptide synthesis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2021-06-08 | — | — | US | disclosed |
| CN-112543763-A | Method for cleaving solid phase bound peptides from solid phase | 赛诺菲-安万特德国有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-3774838-A1 | LIXISENATIDE SYNTHESIS WITH CAPPING | Sanofi-Aventis Deutschland GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774837-A1 | METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | Sanofi-Aventis Deutschland GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218876-A | Synthesis of blocked lixisenatide | 赛诺菲-安万特德国有限公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020146541-A2 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20190330263-A1 | CAPPING OF UNPROTECTED AMINO GROUPS DURING PEPTIDE SYNTHESIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330266-A1 | METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
| WO-2019197469-A1 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197466-A1 | METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119539-A1 | TRACELESS LINKERS AND PROTEIN-CONJUGATES THEREOF | NR3C1, SSB, SERPINA6 | OPRD1 4271/4885PREP 1962/4885KMT2A 2035/4885 |
| US-20190330263-A1 | CAPPING OF UNPROTECTED AMINO GROUPS DURING PEPTIDE SYNTHESIS | RNGTT, ANPEP, DNPEP | OPRD1 3575/4885PREP 9/4885KMT2A 3932/4885 |
| US-11560402-B2 | Method for cleavage of solid phase-bound peptides from the solid phase | VIP, PTMS, CTRC | OPRD1 3423/4885PREP 24/4885KMT2A 4027/4885 |
| US-20190330266-A1 | METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | VIP, PTMS, CTRC | OPRD1 3423/4885PREP 24/4885KMT2A 4027/4885 |
| US-11028123-B2 | Capping of unprotected amino groups during peptide synthesis | RNGTT, ANPEP, DNPEP | OPRD1 3575/4885PREP 9/4885KMT2A 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.